Gilead Licenses Remdesivir To Five Firms
Cipla, Ferozsons, Hetero, Jubilant And Mylan Get Rights
Gilead has announced a raft of licensing agreements with five generics firms to manufacture potential COVID-19 treatment remdesivir for distribution in 127 countries.
You may also be interested in...
Pakistan’s Searle says it has struck a licensing and marketing deal with Bangladesh’s Beximco to market its generic remdesivir in Pakistan as the country grapples with the coronavirus pandemic.
Bangladesh's Beximco has claimed a world first with the launch of a generic version of remdesivir in its domestic market. Local authorities have granted an emergency use authorization for the COVID-19 treatment amid the coronavirus pandemic.
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK